Senan Sultan, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1366461543
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Amgen at 35.5% of the total. Reporting peaked in 2023 at $19,419 and has fallen 88.2% since, to $2,297 in 2025. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 953 payments — averaging $57.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Lilly USA, LLC$10K
- Boehringer Ingelheim$8K
- Tandem Diabetes Care, Inc.$3K
- Abbott$2K
- Tosoh Bioscience, Inc.$2K
- plus $11K from 47 others
Across 1,465 payments — averaging $1736.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Novo Nordisk AS$785K
- AbbVie$328K
- Amgen$158K
- Sanofi-aventis U.S. LLC$77K
- Endo Pharmaceuticals Inc.$71K
- plus $39K from 6 others
What the payments were for
- Speaking & faculty fees$30,95956%
- Travel & lodging$2,9025%
- Food & beverage$19,78536%
- Education$280%
- Gifts$1,5663%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$17,728
- JARDIANCE$15,837
- 25-OH Vitamin D ST AIA-Pack$5,481
- t:slim X2 Insulin Pump with Control-IQ$1,998
- MINIMED 780G$252
- FreeStyle Libre$200
- RYBELSUS$135
- Ozempic$135
- FARXIGA$125
- DEXCOM G7 GSS (161)$125
- Kerendia$125
- FREESTYLE LIBRE 3$125
- Omnipod$118
- FreeStyle Libre 2$109
- DEXCOM G6 TRANSMITTER$101
- INVOKANA$100
How this compares
$55,239 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 503 | $774,157 |
| JardianceEmpagliflozin | 358 | $433,186 |
| MounjaroTirzepatide | 171 | $265,162 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 101 | $156,496 |
| Tresiba Flextouch U-200Insulin Degludec | 119 | $133,196 |
| Tresiba Flextouch U-100Insulin Degludec | 159 | $125,713 |
| JanuviaSitagliptin Phosphate | 118 | $125,001 |
| TrulicityDulaglutide | 87 | $116,810 |
| RybelsusSemaglutide | 42 | $82,304 |
| FarxigaDapagliflozin Propanediol | 59 | $76,133 |
| ProliaDenosumab | 42 | $73,480 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $64,147 |
| Novolog FlexpenInsulin Aspart | 173 | $61,390 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 283 | $54,148 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $45,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $1,556 | $913,472613 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr, Synjardy | $7,921 | $557,012494 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $9,865 | $395,598298 claims |
| MerckJanuvia, Janumet Xr, Janumet | $124 | $165,271148 claims |
| AstraZenecaFarxiga | $797 | $76,13359 claims |
| AmgenProlia | $19,584 | $73,48042 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $757 | $43,40928 claims |
| AbbVieSynthroid | $150 | $9,81998 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $512 | $7,337698 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Wasim DeebJacksonville$286K
- Khurram WadudJacksonville$77K
- Firas WardaJacksonville$38K
- Maria Hurtado AndradeJacksonville$36K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.